The ABCs of AF.

Slides:



Advertisements
Similar presentations
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
NOACs for Cancer-Associated Thrombosis:
Atrial Fibrillation and PCI
NOACs In Long-term VTE Treatment: A State Of The Art Review
Tailoring Statin Therapy in Women
US Guidelines US Guidelines Low-risk Patients.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
When Is Adding Aspirin to NOACs Worth the Risk?
Thrombosis, Cancer, and NOACs
The ABCs of AF.
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
New Perspectives in AF and PCI: Implications for the Practicing Physician.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Individualizing Prophylaxis in Hemophilia
Oral Anticoagulants in AFa,b A Brief History.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
How to Adjust Anticoagulant Dosing
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Are We Closer to Personalized Medicine in MS?
Real-World Safety of NOACs: What Do We Know Today?
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
TAVR and the Risk of Thrombosis
Adherence in SPAF: Measures to Improve Care
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Risk Stratification in CAD and PAD
Oral Anticoagulation in AF
Real-World Evidence in VTE
Dos and Don’ts for High-Risk Elderly Patients With AF
Practical Considerations to Extend Treatment for VTE
Atrial Fibrillation.
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
NOACs in AF: Consequences of Underdosing and NonAdherence
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Identifying High-Risk AF Patients
A Time for Change for Managing Patients With VTE Who Have Cancer
What You Didn't Know About AF and Renal Dysfunction
Cancer-Associated Thrombosis
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Updates in Anticoagulation: Key Sessions at ESC 2017
Program Goals Background: Anticoagulation in Patients With VTE.
NOACs in AF: Consequences of Underdosing and NonAdherence
Elevated Admission Plasma Glucose Following ACS
Clinical Challenges and Updates in Managing Seizure Clusters
5 Good Minutes on Atrial Fibrillation-related Stroke
What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.
NOACs and Reversal Agents
At the Crossroads of Coagulation
How to Adjust Anticoagulant Dosing
Antiarrhythmic Drugs in AF
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Rethinking Risk Stratification for Nonischemic HF:
Extraordinary Cases in Stroke Prevention
What's New in NOACs in AF?.
Treating Pulmonary Embolism Today
Presentation transcript:

The ABCs of AF

Goals

Bleeding With Warfarin

How Frequent Is Bleeding With NOACs?

Bleeding Risk: HAS-BLED

Bleeding Scores in AF

Biomarkers in AF

Reasons for and Implications of Elevated GDF-15 Level

GDF-15 in ARISTOTLE

GDF-15 Strongest Bleeding Marker

Risk Scores Related to Cardiac Biomarker Levels

The Novel ABC (Age, Biomarkers, Clinical History)- Bleeding Risk Score in AF

3 Dimensions of AF Treatment

Validation and Calibration ABC-Bleeding Risk Score

Discrimination With ABC-Bleeding in Comparison With Other Bleeding Risk Scores in AF

Risk Stratification With ABC-Bleeding Within Other Bleeding Scores

ABC Risk Scores in AF

ABC-AF Pragmatic Clinical Study Design

Expected Trial Outcomes: ABC-AF

Future Considerations

Risk Stratification and Biomarkers: Summary

Key Takeaways

Abbreviations

Abbreviations (cont)